Infusion Care neria™
Therapeutic areas for subcutaneous infusion with neria™ infusion sets
neria™ infusion sets are subcutaneous infusion devices – in vitro tested and approved for drug infusion in the treatment of Parkinson’s disease¹, thalassaemia² and primary immune deficiency³ and pain management4,5
Read more about neria™ infusion sets here.
Subcutaneous drug delivery
Subcutaneous infusion delivers medication over a longer period in the fatty tissue beneath the skin, where the medication is absorbed by the body. A needle penetrates the skin, leaving either the needle or a soft catheter to remain in the tissue, from a few hours up to 72 hours. Needles and cannulas can vary in length, size, features and method of insertion. Infusion sets eliminate the need for one or several daily injections of a specific drug.
1 Stability test and function test of Comfort and Contact Detach by means of the medicament APO-go. Analysis report no. 294690. January 14-April 1, 2009. Data on file. Unomedical.
2 Drug Device Stability Test Thalaset – Study Desferal (deferoxamine mesilate). July 1, 2005. Data on file. Unomedical.
3 Compatibility and stability testing of the catheter device Unomedical comfort™ with the immunoglobulin Subcuvia. IKFE 09016. April 16, 2009. Data on file. Unomedical.
4 Drug Compatibility Study of Three Infusion Devices with Morphine Sulfate, version 1.4, IKFE 10006, September 2, 2011, Data on File. Unomedical.
5 Drug Compatibility Study of Three Infusion Devices with Hydromorphone Hydrochloride, version 1.4, IKFE 10006, September 2, 2011, Data on File. Unomedical.